Celcuity receives US patent for its lead drug candidate, gedatolisib; getting exclusivity up to 2042: Minneapolis Thursday, July 17, 2025, 16:00 Hrs [IST] Minneapolis-headquartere ...

Zeno Health launches nationwide e-commerce platform to deliver quality, affordable medicines across 23,000+ pin codes: Our Bureau, Bengaluru Thursday, July 17, 2025, 15:20 Hrs [IS ...

Illumina India, a global leader in sequencing technology, has won the 2025 GCC Workplace Awards, hosted by the Zyoin Group. The award recognizes Illumina India as the leading Global Capability Center ...

The treatment of life-threatening viruses not addressed with approved therapies. The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications.

Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...

HOSMAC inks MoU with Gulf Medical University as industry partner to strengthen healthcare education: Our Bureau, Bengaluru Thursday, July 17, 2025, 14:45 Hrs [IST] HOSMAC, Asia’ ...

Corona Remedies acquires seven brands in cardiology & women’s healthcare from the pharmaceutical division of Bayer in India: Our Bureau, Mumbai Thursday, July 17, 2025, 13:50 Hr ...

Entod Pharma signs MoU with VESCOP to empower young pharma innovators: Our Bureau, Mumbai Thursday, July 17, 2025, 14:15 Hrs [IST] Entod Pharmaceuticals Ltd., a global leader in o ...

IDMA partners with JetSynthesys’ Inclusional for its first-ever major PoSH compliance drive: Our Bureau, Mumbai Thursday, July 17, 2025, 13:40 Hrs [IST] In a landmark move to sh ...

WHO includes ArkBio' paediatric RSV drug, ziresovir in PADO-RSV priority list: Shanghai, China Thursday, July 17, 2025, 14:00 Hrs [IST] Shanghai Ark Biopharmaceutical Co., Ltd. (A ...

Akeso initiates patient enrolling in phase III trial of ivonescimab for first-line treatment of advanced metastatic colorectal cancer: Hong Kong Thursday, July 17, 2025, 13:00 Hrs ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...